182 related articles for article (PubMed ID: 9559755)
1. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis.
Sclar DA; Skaer TL; Robison LM; Galin RS; Legg RF; Nemec NL
J Clin Psychiatry; 1998; 59 Suppl 2():13-7. PubMed ID: 9559755
[TBL] [Abstract][Full Text] [Related]
2. Economic appraisal of citalopram in the management of single-episode depression.
Sclar DA; Skaer TL; Robison LM; Galin RS
J Clin Psychopharmacol; 1999 Oct; 19(5 Suppl 1):47S-54S. PubMed ID: 10507508
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization.
Sclar DA; Robison LM; Skaer TL; Legg RF; Nemec NL; Galin RS; Hughes TE; Buesching DP
Clin Ther; 1994; 16(4):715-30; discussion 74. PubMed ID: 7982260
[TBL] [Abstract][Full Text] [Related]
4. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization.
Sclar DA; Robison LM; Skaer TL; Galin RS; Legg RF; Nemec NL; Hughes TE; Buesching DP; Morgan M
J Int Med Res; 1995; 23(6):395-412. PubMed ID: 8746607
[TBL] [Abstract][Full Text] [Related]
5. One-year costs of second-line therapies for depression.
Sullivan EM; Griffiths RI; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
J Clin Psychiatry; 2000 Apr; 61(4):290-8. PubMed ID: 10830151
[TBL] [Abstract][Full Text] [Related]
6. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
[TBL] [Abstract][Full Text] [Related]
7. Long-term costs of treatment for depression: impact of drug selection and guideline adherence.
Crown WH; Treglia M; Meneades L; White A
Value Health; 2001; 4(4):295-307. PubMed ID: 11705297
[TBL] [Abstract][Full Text] [Related]
8. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
[TBL] [Abstract][Full Text] [Related]
9. Effects of antidepressant treatments on health service utilization and medical costs among patients with depression: a nationwide population-based retrospective cohort study in Taiwan.
Su KP; Tang CH; Chang HC; Chiu WC; Lu N; Huang KC
Int Clin Psychopharmacol; 2019 Jul; 34(4):170-178. PubMed ID: 30964763
[TBL] [Abstract][Full Text] [Related]
10. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of initial antidepressant drug choice in a "real world" randomized trial.
Simon GE; Heiligenstein J; Revicki D; VonKorff M; Katon WJ; Ludman E; Grothaus L; Wagner E
Arch Fam Med; 1999; 8(4):319-25. PubMed ID: 10418538
[TBL] [Abstract][Full Text] [Related]
12. Sociological influences on antidepressant prescribing.
Sleath B; Shih YC
Soc Sci Med; 2003 Mar; 56(6):1335-44. PubMed ID: 12600369
[TBL] [Abstract][Full Text] [Related]
13. Does the use of SSRIs reduce medical care utilization and expenditures?
Chung S
J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
[TBL] [Abstract][Full Text] [Related]
14. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
[TBL] [Abstract][Full Text] [Related]
15. Effect of antidepressant choice on the incidence and economic intensity of hospitalization among depressed individuals.
Croghan TW; Kniesner TJ; Melfi CA; Robinson RL
Adm Policy Ment Health; 2000 Mar; 27(4):183-95. PubMed ID: 10911668
[TBL] [Abstract][Full Text] [Related]
16. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
[TBL] [Abstract][Full Text] [Related]
17. Effect of antidepressant therapy on health care utilization and costs in primary care.
Croghan TW; Lair TJ; Engelhart L; Crown WE; Copley-Merriman C; Melfi CA; Obenchain RL; Buesching DP
Psychiatr Serv; 1997 Nov; 48(11):1420-6. PubMed ID: 9355169
[TBL] [Abstract][Full Text] [Related]
18. Fluoxetine versus other types of pharmacotherapy for depression.
Magni LR; Purgato M; Gastaldon C; Papola D; Furukawa TA; Cipriani A; Barbui C
Cochrane Database Syst Rev; 2013 Jul; (7):CD004185. PubMed ID: 24353997
[TBL] [Abstract][Full Text] [Related]
19. Economic outcomes associated with tricyclic antidepressant and selective serotonin reuptake inhibitor treatments for depression.
Crown WH
Acta Psychiatr Scand Suppl; 2000; 403():62-6. PubMed ID: 11019937
[TBL] [Abstract][Full Text] [Related]
20. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
